Literature DB >> 33436787

Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018.

Giosafat Spitaleri1, Josep Lupón1,2,3, Mar Domingo1, Evelyn Santiago-Vacas1, Pau Codina1, Elisabet Zamora1,2,3, Germán Cediel1,2, Javier Santesmases1,2, Crisanto Diez-Quevedo1, Maria Isabel Troya1, Maria Boldo1, Salvador Altmir1, Nuria Alonso1, Beatriz González1, Julio Núñez3,4,5, Antoni Bayes-Genis6,7,8,9.   

Abstract

To assess mortality trends at 1 and 3 years from 2001 to 2018 in a real-life cohort of HF outpatients from different etiologies with depressed and preserved LVEF. A total of 2368 consecutive patients with HF (mean age 66.4 ± 12.9 years, 71% men, 15.4% with preserved LVEF) admitted to a HF clinic from August 2001 to September 2018 were included in the study. Patients were divided into five quintiles (Q) according to the period of admission. Trends for all-cause and cardiovascular mortality from Q1 to Q5 were assessed by linear regression. Patients with LVEF < 50% had a progressive decrease in the rates of all-cause and cardiovascular death at 1 year (12.1% in Q1 to 6.5% in Q5, p = 0.003; and 8.4% in Q1 to 3.8% in Q5, p = 0.007, respectively) and 3 years (30.5% in Q1 to 17.0% in Q5, p = 0.003; and 23.9% in Q1 to 9.8% in Q5, p = 0.003, respectively). These trends remained significant after adjusting for clinical characteristics and risk. No significant trend in mortality was observed in patients with LVEF ≥ 50%. In a cohort of real-life ambulatory patients with HF, mortality progressively declined in patients with LVEF < 50%, but the same trend was not observed in patients with preserved LVEF.

Entities:  

Year:  2021        PMID: 33436787      PMCID: PMC7804393          DOI: 10.1038/s41598-020-79926-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  29 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  The impact of a nurse-led care programme on events and physical and psychosocial parameters in patients with heart failure with preserved ejection fraction: a randomized clinical trial in primary care in Russia.

Authors:  Anton Andryukhin; Elena Frolova; Bert Vaes; Jan Degryse
Journal:  Eur J Gen Pract       Date:  2010-12       Impact factor: 1.904

3.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study-4, chronic kidney disease epidemiology collaboration, and cockroft-gault formulas.

Authors:  Elisabet Zamora; Josep Lupón; Joan Vila; Agustín Urrutia; Marta de Antonio; Hèctor Sanz; Maria Grau; Jordi Ara; Antoni Bayés-Genís
Journal:  J Am Coll Cardiol       Date:  2012-05-08       Impact factor: 24.094

5.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

6.  Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Authors:  James B Young; Mark E Dunlap; Marc A Pfeffer; Jeffrey L Probstfield; Alain Cohen-Solal; Rainer Dietz; Christopher B Granger; Jaromir Hradec; Jerzy Kuch; Robert S McKelvie; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Peter Held; Scott D Solomon; Salim Yusuf; Karl Swedberg
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

7.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

Authors:  Scott D Solomon; John J V McMurray; Inder S Anand; Junbo Ge; Carolyn S P Lam; Aldo P Maggioni; Felipe Martinez; Milton Packer; Marc A Pfeffer; Burkert Pieske; Margaret M Redfield; Jean L Rouleau; Dirk J van Veldhuisen; Faiez Zannad; Michael R Zile; Akshay S Desai; Brian Claggett; Pardeep S Jhund; Sergey A Boytsov; Josep Comin-Colet; John Cleland; Hans-Dirk Düngen; Eva Goncalvesova; Tzvetana Katova; Jose F Kerr Saraiva; Małgorzata Lelonek; Bela Merkely; Michele Senni; Sanjiv J Shah; Jingmin Zhou; Adel R Rizkala; Jianjian Gong; Victor C Shi; Martin P Lefkowitz
Journal:  N Engl J Med       Date:  2019-09-01       Impact factor: 91.245

8.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

Review 9.  Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Authors:  Sean Lee Zheng; Fiona T Chan; Adam A Nabeebaccus; Ajay M Shah; Theresa McDonagh; Darlington O Okonko; Salma Ayis
Journal:  Heart       Date:  2017-08-05       Impact factor: 5.994

10.  Heart failure disease management: a systematic review of effectiveness in heart failure with preserved ejection fraction.

Authors:  Fotini Kalogirou; Faye Forsyth; Martha Kyriakou; Rhys Mantle; Christi Deaton
Journal:  ESC Heart Fail       Date:  2020-01-24
View more
  2 in total

1.  Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality.

Authors:  Giosafat Spitaleri; Elisabet Zamora; German Cediel; Pau Codina; Evelyn Santiago-Vacas; Mar Domingo; Josep Lupón; Javier Santesmases; Crisanto Diez-Quevedo; Maria Isabel Troya; Maria Boldo; Salvador Altimir; Núria Alonso; Beatriz González; Antoni Bayes-Genis
Journal:  J Clin Med       Date:  2022-01-31       Impact factor: 4.241

2.  Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators.

Authors:  Pau Codina; Elisabet Zamora; Wayne C Levy; Elena Revuelta-López; Andrea Borrellas; Giosafat Spitaleri; Germán Cediel; María Ruiz-Cueto; Elena Cañedo; Evelyn Santiago-Vacas; Mar Domingo; David Buchaca; Isaac Subirana; Javier Santesmases; Rafael de la Espriella; Julio Nuñez; Josep Lupón; Antoni Bayes-Genis
Journal:  Front Cardiovasc Med       Date:  2022-04-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.